{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(3)"],"submitter":["Vazquez-Ortiz G"],"funding":["Intramural NIH HHS"],"pubmed_abstract":["<h4>Introduction</h4>Breast cancer is a devastating disease that results in approximately 40,000 deaths each year in the USA. Current drug screening and chemopreventatitive methods are suboptimal, due in part to the poor specificity of compounds for cancer cells. Poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi)-mediated therapy is a promising approach for familial breast cancers caused by mutations of breast cancer-associated gene-1 and -2 (BRCA1/2), yet drug resistance frequently occurs during the treatment. Moreover, PARPis exhibit very little effect on cancers that are proficient for DNA repair and clinical efficacy for PARPis as single-agent therapies has yet to be illustrated.<h4>Methods</h4>Using a quantitative high-throughput screening approach, we screened a library contain"],"journal":["Breast cancer research : BCR"],"pagination":["R67"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4229979"],"repository":["biostudies-literature"],"pubmed_title":["Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells."],"pmcid":["PMC4229979"],"pubmed_authors":["Vazquez-Ortiz G","Deng C","Lahusen TJ","Li C","Xia M","Xu X","Sakamuru S","Huang R","Thomas CJ","Chisholm C"],"additional_accession":[]},"is_claimable":false,"name":"Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.","description":"<h4>Introduction</h4>Breast cancer is a devastating disease that results in approximately 40,000 deaths each year in the USA. Current drug screening and chemopreventatitive methods are suboptimal, due in part to the poor specificity of compounds for cancer cells. Poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi)-mediated therapy is a promising approach for familial breast cancers caused by mutations of breast cancer-associated gene-1 and -2 (BRCA1/2), yet drug resistance frequently occurs during the treatment. Moreover, PARPis exhibit very little effect on cancers that are proficient for DNA repair and clinical efficacy for PARPis as single-agent therapies has yet to be illustrated.<h4>Methods</h4>Using a quantitative high-throughput screening approach, we screened a library contain","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jun","modification":"2025-04-05T00:20:34.931Z","creation":"2019-03-27T01:39:29Z"},"accession":"S-EPMC4229979","cross_references":{"pubmed":["24962108"],"doi":["10.1186/bcr3682"]}}